Clinical Trial Update: Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating dabrafenib plus trametinib as adjuvant therapy for stage III BRAF V600+ melanoma after complete resection, with results posted a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malignant Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2024-03-18